Olivia Vizier

pharmas almanac

What is your plan to build a more sustainable business practice in the coming years?

Our plan to achieve sustainability as a business practice in the coming years lies within Calliditas’ strategy to execute on our vision to efficiently expand, develop, and market our pipeline of innovative medicines targeting rare diseases that have the potential to improve the lives of patients with

What is your plan to build a more sustainable business practice in the coming years? Read More »

pharmas almanac

What key indicators do you look at to predict the future of this industry?

At Xalud, we’re developing a non-viral plasmid DNA platform that has the potential to change the paradigm in chronic inflammatory diseases by creating a gene therapy for the masses and not just for rare diseases. We have a pipeline with broad potential for our proprietary platform, including several programs in development, and we look forward

What key indicators do you look at to predict the future of this industry? Read More »

pharmavoice

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

But in 2019, he walked away from all of that to become the founder and CEO of Alto Neuroscience, which the company said is “pioneering an approach to psychiatric drug development which matches the right patient with the right Alto drug based on AI-derived brain biomarkers.”

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds Read More »

medsider

Lessons in Leadership — Building a Successful Team and Checking Your Ego at the Door: Interview with Check-Cap Founder and CTO Yoav Kimchy

That’s why Yoav Kimchy, Founder and CTO of Check-Cap, launched the company in 2005 with the goal of creating a technology that could make colorectal screenings easier and less invasive for patients.

Lessons in Leadership — Building a Successful Team and Checking Your Ego at the Door: Interview with Check-Cap Founder and CTO Yoav Kimchy Read More »

Drug Development

PLATFORM TECHNOLOGY – The Evolution of Cancer Vaccines: Moving Beyond Failure & a New Era for Cancer Treatment

IMV is evaluating DPX-based assets in several clinical trials in difficult-to-treat cancer indications, including diffuse large B-cell lymphoma (DLBCL), ovarian, breast, and bladder cancer. Previous studies have shown encouraging results, notably in pa­tients who have failed on prior lines of therapy. MVP-S is the clinical validation and proof of concept of the DPX platform’s potential

PLATFORM TECHNOLOGY – The Evolution of Cancer Vaccines: Moving Beyond Failure & a New Era for Cancer Treatment Read More »

companyweek

CEO Glenn Mattes, VP of Product Development and Manufacturing Dr. John Koleng, and their team are disrupting traditional pharmaceutical development and manufacturing with exciting new technology.

Mattes says there isn’t an official founding date for TFF Pharmaceuticals (NASDAQ TFFP) as the company sprung from another Austin-based organization known as Lung Therapeutics circa 2017.

CEO Glenn Mattes, VP of Product Development and Manufacturing Dr. John Koleng, and their team are disrupting traditional pharmaceutical development and manufacturing with exciting new technology. Read More »

Biotech turns to new and strange viruses to overcome gene therapy’s limitations

The fluorescent orange sticker atop the white machine reads “BIOHAZARD,” but it’s a bit of a misnomer. Although Earth abounds with pathogens that can maim, kill, paralyze, and poison, the specimens inside this machine — being pipetted left and right behind glass for sequencing — are probably the most innocuous human viruses you will ever

Biotech turns to new and strange viruses to overcome gene therapy’s limitations Read More »

PharmTech

Drug Solutions Podcast: Cell Therapy Development: Advances, Trends, and the Challenge of Retention

Experts from Umoja Biopharma dive into cell therapy development in this episode of the Drug Solutions Podcast, including the greatest advancements in cell therapy to date, areas for improvement, the biggest trends in cell therapy development, and retention as a pain point.

Drug Solutions Podcast: Cell Therapy Development: Advances, Trends, and the Challenge of Retention Read More »

pharma shots

Matt Killeen, CSO at Renovacor Shares Insights on Pipeline Expansion through its AAV Gene Therapy Program

We’re developing a pipeline of innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Our lead program, REN-001, is being developed for BAG3-associated dilated cardiomyopathy (DCM) and uses gene transfer technology to address the monogenic cause of this severe form of heart failure.

Matt Killeen, CSO at Renovacor Shares Insights on Pipeline Expansion through its AAV Gene Therapy Program Read More »